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110BACKGROUND The combined left atrial appendage closure (LAAC)
and cryoenergy pulmonary vein isolation (PVI) procedure has been
proven safe and effective in managing stroke in patients with non-
valvular atrial ﬁbrillation (AF), although most data refer to proced-
ures performed using radiofrequency as the main energy source.
OBJECTIVE The purpose of this study was to evaluate long-term
follow-up of patients with AF undergoing concomitant LAAC and
cryoenergy PVI.
METHODS Patients undergoing LAAC and cryoballoon PVI at our
institution were enrolled. At 3, 6, and 24months from the index pro-
cedure, we determined the atrial arrhythmia recurrence rate, the
extent of LAAC, and the rate of cerebrovascular/bleeding events.
RESULTS Forty-nine patients (mean age 69 6 8 years; 67% men;
CHA2DS2-VASc score 2.86 1.2; HAS-BLED score 36 1) with a guide-
line LAAC indication were included. Acute PVI and complete LAAC
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FLA 5.6.0 DTD  HRTHM7955_proo24 months of follow-up. At 8 weeks and 6 months, complete or
satisfactory (,5 mm leak) LAAC rates were achieved in 82% and
18% and in 86% and 14% of patients, respectively. The overall
freedom from atrial arrhythmia rate at 24 months was 60%, and
92% of patients were off antithrombotic drugs. The observed annu-
alized stroke and bleeding rates were 1% and 2%, respectively, a
71% and 60% risk reduction in comparison to event rates predicted
from CHA2DS2-VASc and HAS-BLED scores.
CONCLUSION Concomitant cryoballoon ablation and LAAC proced-
ures appear safe and effective at long-term follow-up, with high an-
tithrombotic drug withdrawal rates at 24 months.
KEYWORDS Atrial ﬁbrillation ablation; Combined procedure; Cryo-
balloon; Intracardiac echocardiography; Left atrial appendage
closure
(Heart Rhythm 2019;-:1–7) © 2019 Heart Rhythm Society.
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121Introduction
Percutaneous left atrial appendage closure (LAAC) is
currently used as a stroke prevention option in patients with
atrial ﬁbrillation (AF) and vitamin K antagonist (VKA) or
non–vitamin K oral antagonist (NOAC) intolerance.1–6
LAAC is usually performed as a stand-alone procedure;
however, the feasibility, safety, and effectiveness of LAAC122
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133alongside concomitant AF catheter ablation (combined pro-
cedure) have been described.
Furthermore, combined procedure studies have reported
outcomes at short-, mid-, and longer-term follow-up,2–6
comparable to the stand-alone LAACwith a later AF catheter
ablation procedure (staged strategy), with the main advantage
of bringing the patient into the operating room once.2,11 Q
Recent studies of combined procedures have been almost
exclusively focused on irrigated/nonirrigated radiofrequency
catheter ablation with regard to the AF ablation procedure.2,9
To date, longer-term data on the combined procedure with
cryoballoon ablation procedures are lacking, with only a sin-
gle study from our group describing a smaller cohort with
mid-term follow-up.3
In this study, we report the long-term outcome of com-
bined LAAC and cryoballoon catheter ablation procedures
performed in a single center over a 7-year time frame.https://doi.org/10.1016/j.hrthm.2019.03.022
134
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228Methods
Study population
In this survey, we enrolled patients undergoing a combined
cryoballoon ablation and LAAC procedure at our institution
from January 2010 to January 2017, with at least 24 months
of follow-up. The combined procedure represented the ﬁrst
catheter ablation procedure in all cases; no combined proced-
ure as a redo of a previous AF ablation procedure was
enrolled.
LAAC indication was set because of a high bleeding risk/
previous major bleeding event in antithrombotic therapy or
because of a previous ischemic event despite antithrombotic
therapy; our center’s LAAC indications complied with the
Munich consensus document since its publication in 2016.1
Patients with either paroxysmal, persistent, or long-
standing persistent AF were included. The study was
approved by both scientiﬁc and ethical review boards at
our institution and complies with the Declaration of Helsinki.
Patients gave informed consent, and data were retrieved from
a central de-identiﬁed database.229
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244Procedural planning
Within 7 days before the procedure, all patients underwent
transesophageal echocardiography (TEE) or a contrast car-
diac computed tomography scan to rule out left atrial
appendage (LAA) thrombi and to assess LAA anatomy.
The combined procedure was performed with uninterrupted
antithrombotic regimen according to current clinical practice.
All procedures were performed by experienced operators
(with .50 cryoballoons and .20 LAAC procedures per
year).10 Moreover, all physicians involved were a part of a
dedicated team to minimize the learning curve effect within
the study.15
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272Cryoballoon ablation
The arrhythmia ablative protocol comprised a pulmonary
vein isolation (PVI) procedure through cryoenergy. Cryoa-
blation procedures were performed as previously described3
in accordance with the 2017 expert consensus.11 In brief, a
single transseptal puncture was performed under ﬂuoroscopy
and/or intracardiac echocardiography (ICE, Abbott, XXXX,
CA) guidance. A 28-mm second-generation cryoballoon
(Arctic Front Advance, Medtronic, XXXX, MN) was
inserted through a steerable sheath (FlexCath, Medtronic)
in the left atrium (LA). Notably, in the ﬁrst 9 cases, the
ﬁrst-generation cryoballoon (Arctic Front, Medtronic) was
used because the second-generation cryoballoon was not
commercially available in Europe. During right-sided pulmo-
nary vein (PV) cryoablation procedures, phrenic nerve
pacing was conducted to monitor nerve function and dia-
phragmatic response; cryoablation procedures were termi-
nated at the ﬁrst sign of diminished diaphragmatic
response. PVI was conﬁrmed by positioning the Achieve
mapping catheter to the ostium most proximal site. By con-
ventional pacing maneuver, complete bidirectional block
along the PV-LA junction was assessed.FLA 5.6.0 DTD  HRTHM7955_prooLAAC
In conjunction with ICE and ﬂuoroscopy guidance, LAAC
procedures were performed under 2- or 3-dimensional ultra-
sound guidance. All LAACprocedureswere performed as pre-
viously described.3 In brief, a Watchman device (Boston
Scientiﬁc, MA) or the Amplatzer Cardiac Plug (Abbott, CA)
was used to occlude the LAA. When using ICE, the probe
was moved into the LA by crossing the atrial septum alongside
the ﬁrst transseptal puncture andwas then placed in front of the
LAA for direct visualization. A 10%–25% upsizing in device
dimension was routinely performed to promote effective
compression for device stability. Before device release, the
following procedural criteria had to be met: (1),3 mm resid-
ual lateral ﬂow, (2) absence of mitral valve interference, (3)
correct device position in relation to the circumﬂex artery
plane, and (4) conﬁrmed device stability by a tug test.Acute procedural outcomes
Acute catheter ablation success, LAA occlusion, and peripro-
cedural adverse events were assessed during all procedures.
Periprocedural adverse events were deﬁned as follows: (1)
serious pericardial effusions requiring drainage, (2) acute
device embolization (,24 hours) assessed by TEE and ﬂuo-
roscopy, (3) procedure-related transient ischemic attack
(TIA)/stroke, and (4) vascular adverse events (major bleeding,
groin hematoma, pseudoaneurysm, and arteriovenous ﬁstula).Patient postprocedural management and follow-up
All patients (excluding inherited bleeding disorders that
received only low-molecular-weight heparin [LMWH]) were
discharged on LAAC device guideline-recommended antith-
rombotic regimen, speciﬁcally aspirin 1 warfarin/NOAC/
LMWH following Watchman occlusion or VKA/NOAC/
LMWHor aspirin and clopidogrel in case of absolute contrain-
dication to anticoagulants following Amplatzer occlusion.
These regimens were maintained for at least 2 months.
Eight-week follow-up TEEwas recommended to assess de-
vice placement and residual leakages. Device positioning was
denoted as “satisfactory” if peridevice ﬂowwas,5mmand as
“optimal” if no peridevice ﬂow was detectable12; second TEE
was repeated at 6 months. Patient follow-up visits were sched-
uled at 6, 12, and every 12months thereafter. Atrial arrhythmia
recurrence was assessed at all visits by symptom reporting,
baseline electrocardiography, and 24-hour Holter monitoring
electrocardiography.
Given satisfactory LAA occlusion at 8 weeks, antithrom-
botic therapy was de-escalated. Speciﬁcally, Watchman de-
escalation called for a switch to dual antiplatelet therapy (75
mg clopidogrel plus 100mg aspirin) for 6months and then life-
long 100 mg aspirin; the Amplatzer de-escalation protocol
instead called for a 100mgaspirin regimen for at least 3months.Long-term outcome analyses
For the LAAC efﬁcacy analysis, data on the occurrence of
TIA/stroke or systemic embolism were collected Q. In addition,
all bleeding events were considered according to thef  10 May 2019  8:11 am  ce
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354Bleeding Academic Research Consortium criteria.13 Stroke
and bleeding reduction risk was assessed by comparing the
normalized observed rate of events per year of follow-up
with the expected rate of events per year derived from
CHA2DS2-VASc and HAS-BLED scores as per validation
studies.14 For the cryoballoon ablation efﬁcacy analysis, all
supraventricular arrhythmias (atrial ﬂutter, AF, or atrial
tachyarrhythmia) lasting.30 seconds after a 3-month blank-
ing period were considered.
Per study protocol, outcome analyses were performed at 6
months (short-term), 12 months (mid-term), and 24 months
(long-term).355
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371Statistical analysis
Statistical analyses were performed using Stata version 15.0
(StataCorp LLC, XXXX, TX). Normality for continuous vari-
ables was assessed using the Shapiro-Wilk test. Continuous
variables were expressed as mean 6 SD or as median (inter-
quartile range) for normally and nonnormally distributed vari-
ables, respectively. Categorical variables were expressed as
count (percentage). Kaplan-Meier survivorship estimates
were used to summarize outcome data. Comparison analyses
between groups were performed using the Student t test or
the Kruskal-Wallis test, as appropriate. A P value of ,.05
was considered signiﬁcant.Table 1 Baseline demographic characteristics (N 5 49)
Characteristic Value
Age (y) 69 6 8
Sex: male 32 (67)
AF type
Paroxysmal AF 25 (51)
Persistent AF 16 (33)
Long-standing persistent AF 8 (17)
LVEF (%) 54 6 5
CHA2DS2-VASc score 2.8 6 1.2
Chronic heart failure 4 (8)
Age between 65 and 74 y 26 (53)
Age .74 y 11 (22)
Hypertension 39 (80)
Vascular disease* 5 (10)
Diabetes 11 (23)
Previous stroke/TIA 23 (47)
On OAT 16 (70)
HAS-BLED score 3 6 1
Impaired renal function 3 (6)
Impaired liver function 1 (2)
History of stroke 19 (39)
History of bleeding 28 (57)
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396Results
Baseline patient population
Forty-nine patients undergoing a combined LAAC and cryo-
balloon ablation procedure were enrolled (mean age 69 6 8
years; 67% men). Paroxysmal AF was present in 51% of pa-
tients, whereas 33% and 17% suffered from persistent AF
and long-standing persistent AF, respectively. Stroke
(CHA2DS2-VASc) and hemorrhage (HAS-BLED) risk
scores were 2.8 6 1.2 and 3 6 1, respectively. LAAC indi-
cations were as follows: (1) previous stroke/TIA despite an-
tithrombotic therapy in 16 of 49 patients (33%), (2) previous
major bleeding event(s) in 14 of 49 patients (29%), (3) labile
international normalized ratio in 4 of 49 (8%), (4) blood
dyscrasia with absolute antithrombotic therapy contraindica-
tion in 5 of 49 (10%), (5) chronic anemia from recurrent
bleeding in 3 of 49 (6%), (6) high hemorrhagic risk (eg,
HAS-BLED score .3) in 5 of 49 (10%), and (7) antithrom-
botic therapy intolerance/refusal in 2 of 49 (4%).
Table 1 reports baseline clinical characteristics.
Labile INRs 6 (12)
Drug abuse 3 (6)
Alcohol abuse 3 (6)
Inherited bleeding disorders 5 (10)
397
398
399
400Procedural data
All procedural data are reported in Table 2.Hemophilia 3 (6)
von Willebrand 2 (4)
Values are presented as mean 6 SD or as n (%).
AF5 atrial ﬁbrillation; INR5 international normalized ratio; LVEF5 left
ventricular ejection fraction; OAT5 oral anticoagulant therapy; TIA5 tran-
sient ischemic attack.
*Deﬁned as previous myocardial infarction, peripheral artery disease, or
aortic plaque.
401
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408Cryoballoon ablation
A 28-mm ﬁrst-generation and a second-generation cryobal-
loon was used in 9 (18%) and 40 (82%) cases, respectively.
Total PV occlusion and acute PVI were achieved in all pa-
tients. One transient phrenic nerve palsy occurred while
ablating the right superior PV; palsy complete resolutionFLA 5.6.0 DTD  HRTHM7955_proowas demonstrated during the second follow-up visit (postpro-
cedural day 60).LAAC
The LAAC device was placed immediately after cryoballoon
ablation. In 34 cases (70%), TEE and ﬂuoroscopy imaging
was used to guide the procedure, while in 15 (30%), ICE
and ﬂuoroscopy were used. In 6 (12%) cases, ICE was
used alongside TEE, and these cases represented the early
beginning of the ICE-guided LAAC experience at our center.
An Amplatzer device was used in 39 patients (80%), while
the Watchman device was used in 10 (20%). The acute im-
plantation success rate was 100%, with only 3 patients
(6%) requiring device recapture(s) and redeployment(s).
No major procedural complications were encountered,
aside from 2 vascular complications (4%) (n 5 1, self-
resolving groin hematoma; n 5 1, arteriovenous ﬁstula
requiring surgery). In 43 patients (88%), complete LAA oc-
clusion was obtained, while in 6 (12%), ,3 mm residual
lateral ﬂow was visualized at the end of the procedure. Of
these 6 residual leaks, 5 (83%) were delivered under TEE
guidance and only 1 (17%) under ICE guidance. At the
time of the 24-hour cardiac ultrasound procedure, 4 patients
(8%) had minimal pericardial effusion, with no need for
percutaneous drainage.f  10 May 2019  8:11 am  ce
Table 2 Periprocedural data (N 5 49)
Variable Value
Cryoballoon PVI 49 (100)
Overall procedure time (min) 148 6 31
Cryoablation procedure time (min) 107 6 26
LAAC procedure time (min) 40 6 9
Overall ﬂuoroscopy time (min) 30 6 6
Cryoablation ﬂuoroscopy time (min) 22 6 9
LAAC ﬂuoroscopy time (min) 9 6 2
Device
Amplatzer 9 (80)
Watchman 10 (20)
TEE guidance 34 (70)
Complete occlusion 29 (86)
Residual (,3 mm) lateral ﬂow 5 (14)
Pericardial effusion 3 (9)
ICE guidance 15 (30)
Complete occlusion 14 (94)
Residual (,3 mm) lateral ﬂow 1 (6)
Pericardial effusion 1 (6)
Recapture and redeployments
None 46 (94)
1 2 (4)
2 1 (2)
Major complications
Drainage requiring pericardial
effusion
0 (0)
Device embolization 0 (0)
Stroke/TIA 0 (0)
Vascular events 2 (4)
In-hospital length of stay (d) 3.2 6 0.6
Values are presented as mean 6 SD or as n (%).
ICE 5 intracardiac echocardiography; LAAC 5 left atrial appendage
closure; PVI 5 pulmonary vein isolation; TEE5 transesophageal echocardi-
ography; TIA 5 transient ischemic attack.
Table 3 Clinical follow-up data (N 5 49)
Variable Value
Follow-up time (mo) 42 (25–58)
Freedom from arrhythmia recurrences
At 6 mo 42/49 (85)
Paroxysmal AF 23/25 (92)
Persistent AF 13/16 (81)
Long-standing persistent AF 6/8 (75)
At 12 mo 37/49 (76)
Paroxysmal AF 21/25 (84)
Persistent AF 11/16 (68)
Long-standing persistent AF 5/8 (63)
At 24 mo 29/49 (60)
Paroxysmal AF 17/25 (68)
Persistent AF 9/16 (56)
Long-standing persistent AF 3/8 (38)
Redo procedure 11/49 (22)
LAAC follow-up
At 8 wk
Complete occlusion 40/49 (82)
Satisfactory occlusion (,5 mm
leak)
9/49 (18)
Interatrial residual shunt 2/49 (4)
At 6 mo
Complete occlusion 42/49 (86)
Satisfactory occlusion (,5 mm
leak)
7/49 (14)
Interatrial residual shunt 0/49 (0)
Device embolization 0/49 (0)
Device thrombus 1/49 (2%)
Ischemic events 1/49 (2)
TIA 1/49 (2)
Stroke 0/49 (0)
Major bleeding 2/49 (4)
Intracranial 0/49 (0)
Gastrointestinal 2/49 (4)
Pulmonary 0/49 (0)
Urinary 0/49 (0)
Observed annualized bleeding rate (%) 2
Observed annualized ischemic rate (%) 1
Death 1/49 (2)
VKA/NOAC off
At 3 mo 42/49 (86)
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520Follow-up
All patients completed at least 24 months of follow-up with a
median follow-up time of 42 months (interquartile range 25–
58 months) and an average of 4 6 1 follow-up encounters.
Complete follow-up data have been reported in Table 3.17
At 6 mo 43/49 (88)
At 24 mo 45/49 (92)
Values are presented as median (interquartile range), as n/N (%), or as
percentage Q29.
AF 5 atrial ﬁbrillation; LAAC 5 left atrial appendage closure; NOAC 5
non–vitamin K oral anticoagulant; TIA 5 transient ischemic attack; VKA 5
vitamin K antagonist.
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539Arrhythmia recurrence
At the predeﬁned scheduled times, 42 of 49 (85%), 37 of 49
(76%), and 29 of 49 (60%) patients were free from arrhythmia
recurrences at the 6-, 12-, and 24-month follow-up visit,
respectively. Kaplan-Meier curves are shown in Figure 1.
At 24 months, AF recurrences represented the main
arrhythmic index event (11 of 20), followed by atrial tachy-
arrhythmias (7 of 20) and atypical atrial ﬂutters (3 of 20).
After arrhythmia recurrences, 11 patients (22%) elected to
have redo ablation (n5 6, PVI touch-up due to PV electrical
reconnection at long-term; n5 3, PVI radiofrequency touch-
up and posterior wall electrical isolation; n 5 2, posterior
wall radiofrequency electrical isolation); the others were
managed with antiarrhythmic drugs.540
541
542
543
544LAAC follow-up
All patients underwent scheduled 8-week and 6-month TEE.
At 8 weeks, TEE demonstrated a complete or satisfactoryFLA 5.6.0 DTD  HRTHM7955_prooappendage occlusion in 40 (82%) and 9 (18%) patients,
respectively. At 6 months, the same parameters were
recorded in 42 (86%) and 7 (14%) patients, respectively.
Also, at 8 weeks, 2 interatrial shunts (4%) were detected:
both cases resulted resolved Qat 6-month TEE. No device
embolization/displacement was observed.
In 1 patient, at 8 weeks an echogenic structure (suspicious
for device thrombosis) within a noncompletely occluded (,3
mm leakage) appendage was visualized; NOAC therapy was
continued for another month, after which a TEE repetition
demonstrated complete device occlusion with no residual
thrombosis. A single ischemic stroke (64-year-old man treatedf  10 May 2019  8:11 am  ce
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Figure 1 A: Overall long-term follow-up and freedom from arrhythmia
recurrence. B: Long-term freedom from arrhythmia recurrence by atrial
ﬁbrillation type.
p
ri
n
t
&
w
e
b
4
C
=
F
P
O
Figure 2 Annualized bleeding and stroke rate reduction from those risk
predicted Q30from HAS-BLED and CHA2DS2-VASc scores in our population
after the combined procedure.
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662with dual antiplatelet therapy at 5 months from the procedure)
was reported over 24 months of follow-up, resulting in a 1%
observed annualized risk rate. The a priori expected stroke
rate derived from the CHA2DS2-VASc score was 3.5% per
year, resulting in a 71% stroke risk reduction. Two major
bleeding events (4%) were observed (n 5 1, gastric hemor-
rhage in a patient treated with a NOAC at 3 months; n 5 1,
severe large bowel bleeding in a patient treated with dual anti-
platelet therapy), with no hemorrhagic deaths reported. The
observed annualized bleeding rate was 2%, lower than the
4.9% per year a priori expected rate derived from the HAS-
BLED score (60% bleeding risk reduction) (Figure 2).21
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680Long-term antithrombotic therapy management
At 3 months, only 7 patients (14%) received oral anticoag-
ulants (53% NOACs and 47% VKAs) because most pa-
tients had switched to either dual (6 patients [11%]) or
single (28 patients [59%]) antiplatelet therapy. In addition,
8 patients (16%) received no therapy at all. At the 24-
month follow-up visit, 4 patients (8%) received oral antico-
agulant therapy, 5 (10%) used dual antiplatelet therapy, 26
(53%) used only a single antiplatelet drug, and 14 (29%)
received no therapy at all. Consequently, the overall per-
centage of patients off oral anticoagulant therapy at 24
months was 92%, including patients experiencing
arrhythmia recurrences. A graphical representation of thera-
peutic regimens is shown in Figure 3.FLA 5.6.0 DTD  HRTHM7955_prooDiscussion
To our knowledge, this study is the ﬁrst long-term follow-up
analysis on combined cryoballoon catheter ablation of AF
and LAAC. Recently, 2 large and pivotal experiences Qof
the combined procedure were published. Phillips et al6
conﬁrmed the safety and feasibility of the combined proced-
ure approach and described favorable 30-day follow-up data
in a large patient cohort. In addition, Wintgens et al9 pub-
lished the largest multicenter long-term combined procedure
follow-up analysis, with w350 combined procedures. The
annualized thromboembolic and bleeding risk reduction
reported in this second study was 76% and 71%, with a me-
dian follow-up time of 34.5 months Q. A 51% arrhythmia recur-
rence rate was reported by using radiofrequency as the only
catheter ablation energy source for PVI. Long-term data on
cryoballoon combined procedures are generally lacking
(or limited to short-term follow-up), and the main aim of
this study was to partially ﬁll that void.
This study also aimed to strengthen feasibility and safety
data on the combined procedure and its usefulness in a
selected population of patients with nonvalvular AF.Cryoballoon ablation and LAAC combined
procedures
In our study, cryoenergy was chosen as the preferred energy
source for PVI. According to recent AF ablation guidelines
and position papers,15,16 cryoablation has been proven to
be as effective as radiofrequency in PVI and less associated
with intraprocedural thrombi.17
An “extended” AF ablative approach (eg, posterior wall
isolation or an isoprenaline challenge for extrapulmonary
AF foci ablation), for which radiofrequency may be more
effective, has not yet been introduced in the combined pro-
cedure protocol, and several recent experiences proved
cryoablation PVI to be effective in both patients with persis-
tent AF and those with long-standing persistent AF.16 Conse-
quently, cryoballoon ablation represents a viable option, as
already demonstrated in a feasibility paper from our group,3
of which this study represents a prosecution Q.f  10 May 2019  8:11 am  ce
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Figure 3 Changes in antithrombotic regimens during the study. Full lines
indicate conﬁrmed therapy; dashed lines indicate change in therapy.DAPT5
dual antiplatelet therapy; NOAC5 non–vitamin K oral antagonist; VKA5
vitamin K antagonist.
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816In our population, acute procedural success was obtained
in all patients, which is in accordance with recent articles re-
porting success rates of 97%–100%.2,9,19 At long-term
follow-up, we experienced a 60% recurrence rate, compara-
ble to the one reported by Wintgens et al9 when using radio-
frequency and similar to those reported in the literature when
stratifying by AF patterns.20 When including redo ablation
procedures, the overall freedom from arrhythmia rate
increased from 60% to 75%.
Per protocol, our ﬁrst procedure ablative approach was
limited to PVI isolation; no electroanatomic mapping or
isoprenaline challenge for the detection of extrapulmonary
arrhythmic foci was performed. Although observed recur-
rence rates are in accordance with those in the literature for
similar AF patterns, a future study including PVI, posterior
wall isolation, and possibly LAA isolation as part of the com-
bined procedure should be planned to try to further improve
the arrhythmic outcome.
In agreement with LAAC success rates reported in other
studies, successful device placement was obtained in all pa-
tients, with complete sealing at 6 months achieved in a high
percentage of the population (88%). Only a small fraction of
patients presented persistent residual lateral ﬂow (,5 mm),
which is not considered a predictor of thromboembolic
events.19 A single thromboembolic event was reported over
the entire follow-up period. The patient had a completely
sealed LAA at the 6-month follow-up visit but still developed
an ischemic stroke. When comparing the observed and
expected annualized stroke rates, the combined LAAC and
cryoablation procedures appear to be effective in stroke risk
reduction, reaching the 70%–75% stroke risk reduction
reported in the scientiﬁc literature.7
No signiﬁcant differences in arrhythmia recurrence,
thromboembolic, or bleeding rates were found in patients un-
dergoing LAAC with Amplatzer or Watchman devices,
which is in agreement with previous experiences of combined
procedures performed with a mixture of occluder devices.3,5
A high percentage of our population (88%) obtained
freedom from oral anticoagulant therapy at the 6-month
follow-up visit, regardless of arrhythmia recurrences. TheseFLA 5.6.0 DTD  HRTHM7955_proodata may support the idea of using a combined procedure
in those patients with a high bleeding risk and who are ex-
pected to have arrhythmia recurrences (eg, patients with
persistent or long-standing persistent AF). In case of a
long-term failure of cryoballoon ablation, the LAAC device
represents a good backup strategy, allowing the patient not
to reinitiate the oral anticoagulant therapy upon arrhythmia
recurrence.
Given the elevated bleeding risk of most candidates to this
procedure, the main drawback is represented by the postpro-
cedural anticoagulation regimen that should be continued for
at least 2 months. Two hemorrhagic events were observed in
our subpopulation, picturing a 60% bleeding risk reduction,
which is slightly lower than the one reported in the literature.9
In our opinion, this might depend on this postprocedural oral
anticoagulation regimen. A lighter postprocedural antithrom-
botic drug may be proposed in the future, but only for a
selected population with a lower a priori stroke risk.
Interestingly, no ischemic/bleeding events were experi-
enced in the 5 patients with inherited bleeding disorders Q.
This subpopulation represents a conundrum in treating AF
because of the absolute contraindication to oral anticoagula-
tion therapy. An Amplatzer device was preferred in this sub-
population because of a quicker de-escalating postprocedural
drug regimen and LMWH for 2 months as postprocedural
treatment was used. At long-term follow-up, none of those
patients were receiving any treatment and the results were
more than satisfactory. In this subgroup, the combined pro-
cedure is an option that at least deserves to be taken into
consideration.
Finally, we also wish to highlight the low periprocedural
complication rate experienced in our population Q(in accor-
dance with the literature reported rates for experienced high
ﬂow centers Q)9 while reducing the number of vascular access
points and atrial septal punctures needed.21,22ICE in the combined procedure: Our experience
Since 2016, we routinely use ICE technology for real-time
guidance in device delivery. Only 15 patients underwent a
combined procedure under ICE guidance, so the sample
size is still too small to draw deﬁnitive conclusions.
Nonetheless, some ﬁrst preliminary conclusions can be
postulated: (1) In many centers, ICE can be routinely used
during cryoablation procedures, and so the usage as a part
of the LAAC procedure would not carry any extra monetary
cost and could represent a viable alternative in patients with a
contraindication to TEE imaging; (2) in our experience, ICE
measurements of the LAA proved reliable, with no device
embolization or the need for a different sized device after
standard upsizing; (3) unlike TEE, ICE did not require either
general anesthesia during the procedure or a dedicated oper-
ator Q. The main drawbacks of ICE usage were suboptimal
color Doppler function and, to date, the unavailability of 3-
dimensional reconstruction.
To date, the effect of ICE on LAAC and combined proced-
ure has been analyzed only in small real-world clinicalf  10 May 2019  8:11 am  ce
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needed for further evaluations and more solid conclusion.
Limitations
Our study is a retrospective study with a too small sample
size to draw deﬁnitive conclusions. Although not statistically
signiﬁcant, the obtained arrhythmia recurrence rates (as well
as stroke and bleeding risk reduction) are similar to the ones
reported in the literature for similar procedures. The data set
could (potentially) reach statistical signiﬁcance if the sample
size was increased, but further prospective studies are
required to conﬁrm these results. It should also be noted
that the combined procedure as a whole is currently not
part of any international guidelines and requires careful pa-
tient selection and individualized postdischarge antithrom-
botic therapy, representing a highly speciﬁc tailored therapy.
Conclusion
Our study proves the longer-term safety and efﬁcacy of cryo-
balloon combined procedures. Given the increasing number
of centers choosing cryoenergy as anAFablation energy source
over radiofrequency, the opportunity of using a similar
approach for combined procedures should be considered. ICE
usage in LAACdevice deployment seems to offer some advan-
tages that should be addressed in a separate and dedicated
study.
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